XTL Biopharmaceuticals to Acquire AI Data Company Social Proxy
Ticker: XTLB · Form: 6-K · Filed: Jun 5, 2024 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $430,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, ai, data-extraction
TL;DR
XTL is buying an AI data company called Social Proxy to expand into new tech sectors.
AI Summary
On June 5, 2024, XTL Biopharmaceuticals Ltd. (XTL) announced it entered into a definitive share purchase agreement to acquire THE SOCIAL PROXY Ltd. (Social Proxy), an AI web data company. Social Proxy develops an ethical, IP-based proxy and data extraction platform for AI and BI applications.
Why It Matters
This acquisition signals XTL's strategic move into the AI and data extraction space, potentially diversifying its business beyond traditional biopharmaceuticals.
Risk Assessment
Risk Level: medium — The acquisition involves integrating a new technology company, which carries inherent integration and market adoption risks.
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — Acquiring company
- THE SOCIAL PROXY Ltd. (company) — Target company
- Social Proxy (company) — Abbreviated name for target company
- June 5, 2024 (date) — Date of definitive share purchase agreement
FAQ
What is the primary business of THE SOCIAL PROXY Ltd.?
THE SOCIAL PROXY Ltd. is an AI web data company that develops and powers a unique ethical, IP based, proxy and data extraction platform for AI and BI Applications at scale.
What is the nature of the agreement between XTL Biopharmaceuticals and THE SOCIAL PROXY Ltd. shareholders?
XTL Biopharmaceuticals entered into a definitive share purchase agreement with the current shareholders of THE SOCIAL PROXY Ltd.
When was the definitive share purchase agreement entered into?
The definitive share purchase agreement was entered into on June 5, 2024.
What is the purpose of Social Proxy's platform?
Social Proxy's platform is designed for AI and BI applications at scale, providing ethical, IP-based proxy and data extraction capabilities.
Does this filing indicate XTL Biopharmaceuticals' annual report filing status?
This filing indicates that XTL Biopharmaceuticals files annual reports under Form 20-F, as indicated by the checkmark next to 'Form 20-F'.
Filing Stats: 1,010 words · 4 min read · ~3 pages · Grade level 17.4 · Accepted 2024-06-05 09:20:03
Key Financial Figures
- $430,000 — of the Company and (b) the payment of US$430,000 to the shareholders of the Social Proxy
Filing Documents
- ea0207353-6k_xtlbio.htm (6-K) — 17KB
- ea020735301ex99-1_xtlbio.htm (EX-99.1) — 223KB
- ea020735301ex99-2_xtlbio.htm (EX-99.2) — 15KB
- 0001213900-24-049874.txt ( ) — 257KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 5, 2024 XTL BIOPHARMACEUTICALS LTD. By: /s/ Shlomo Shalev Shlomo Shalev Chief Executive Officer 3